CASIF

CASI Pharmaceuticals, Inc. CASIF

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $43.1M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$20.71M

Quarter to Dec 31

Net income

$-48.06M

Quarter to Dec 31

Free cash flow

$-20.77M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$17 total
WEST PACES ADVISORS INC.
$17New
See all 1 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Debt/Equity

FY 2025
EDGAR

Loading ratio trend…

CASIF key financials by period

Reported revenue, net income and operating margin by fiscal year, from CASI Pharmaceuticals, Inc.'s annual filings on SEC EDGAR.

CASI Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$20.7M$-48.1M—
FY 2024$28.5M$-39.3M-138.8%
FY 2023$33.9M$-27.0M-74.0%
FY 2022$43.1M$-41.0M-79.0%
FY 2021$30.2M$-36.7M-137.6%
FY 2020$15.1M$-48.3M—
Source: CASIF filings on SEC EDGAR →

About CASI Pharmaceuticals, Inc. (CASIF): stock profile, AI score and financials

CASI Pharmaceuticals, Inc. (CASIF) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CASIF is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $43.1m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), CASI Pharmaceuticals, Inc. reports quarterly revenue of $20.7M, net income of $-48.1M, free cash flow of $-20.8M. CASIF trades on the Nasdaq exchange and files with the SEC under CIK 1962738. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CASIF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CASI Pharmaceuticals, Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 1962738 →